{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:42:49Z","timestamp":1774129369617,"version":"3.50.1"},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,7,6]]},"DOI":"10.18632\/oncotarget.25714","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T13:32:06Z","timestamp":1530883926000},"page":"29944-29956","source":"Crossref","is-referenced-by-count":9,"title":["Tolerability of obinutuzumab therapy in patients with rituximab-relapsed\/refractory B-cell malignancies - a retrospective single center cohort study"],"prefix":"10.18632","volume":"9","author":[{"given":"Theo","family":"Pirich","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Zwickl-Traxler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pecherstorfer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Jaffe","year":"2016","journal-title":"Blood"},{"key":"2","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Buske","year":"2015","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Rai","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"4","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1001\/jama.2014.14553","article-title":"Chronic lymphocytic leukemia: a clinical review","volume":"312","author":"Rosen","year":"2014","journal-title":"JAMA"},{"key":"5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Pasternack","year":"1975","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Jacquillat","year":"1981","journal-title":"Cancer"},{"key":"7","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Kipps","year":"2008","journal-title":"Blood"},{"key":"8","first-page":"42","article-title":"Chronic lymphocytic leukemia: staging and prognostic factors","volume":"25","author":"Cheson","year":"1998","journal-title":"Semin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials","volume":"91","author":"Group","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/s0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Zinzani","year":"2010","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1200\/jco.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Buhler","year":"2012","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Samoylova","year":"2014","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Lipsky","year":"2015","journal-title":"Lancet Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Devereux","year":"2015","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/s1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Munasinghe","year":"2017","journal-title":"Lancet Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/ajh.24200","article-title":"Follicular lymphoma: 2015 update on diagnosis and management","volume":"90","author":"Freedman","year":"2015","journal-title":"Am J Hematol"},{"key":"18","doi-asserted-by":"publisher","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Ladetto","year":"2014","journal-title":"Ann Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study","volume":"29","author":"Wahlin","year":"2015","journal-title":"Leukemia"},{"key":"20","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1200\/jco.2010.32.9193","article-title":"Primary follicular lymphoma of the duodenum is a distinct mucosal\/submucosal variant of follicular lymphoma: a retrospective study of 63 cases","volume":"29","author":"Raderer","year":"2011","journal-title":"J Clin Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/jco.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Habermann","year":"2013","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/jco.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Lister","year":"2007","journal-title":"J Clin Oncol"},{"key":"23","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Tubiana","year":"1971","journal-title":"Cancer Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Doyen","year":"2004","journal-title":"Blood"},{"key":"25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Mauch","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"26","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/leu.2014.91","article-title":"How we manage follicular lymphoma","volume":"28","author":"Cheson","year":"2014","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Linch","year":"2003","journal-title":"Lancet"},{"key":"28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/s1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Jack","year":"2014","journal-title":"Lancet Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Engert","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Pedersen","year":"2011","journal-title":"Lancet"},{"key":"31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1200\/jco.2015.61.3968","article-title":"Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35\/03","volume":"34","author":"Lohri","year":"2016","journal-title":"J Clin Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2217\/fon.15.57","article-title":"A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas","volume":"11","author":"Feugier","year":"2015","journal-title":"Future Oncol"},{"key":"33","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Lindstrom","year":"2011","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/sonc.2003.50025","article-title":"The mechanisms of action of rituximab in the elimination of tumor cells","volume":"30","author":"Glennie","year":"2003","journal-title":"Semin Oncol"},{"key":"36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies","volume":"34","author":"Fingerle-Rowson","year":"2017","journal-title":"Adv Ther"},{"key":"37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Stilgenbauer","year":"2015","journal-title":"Oncol Res Treat"},{"key":"38","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Jager","year":"2010","journal-title":"Blood"},{"key":"39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4161\/mabs.28282","article-title":"Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia","volume":"6","author":"Byrd","year":"2014","journal-title":"MAbs"},{"key":"40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/19420862.2016.1269580","article-title":"Antibodies to watch in 2017","volume":"9","author":"Reichert","year":"2017","journal-title":"MAbs"},{"key":"41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.phrs.2015.07.003","article-title":"Antibody modulation: Limiting the efficacy of therapeutic antibodies","volume":"99","author":"Beers","year":"2015","journal-title":"Pharmacol Res"},{"key":"42","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Lugtenburg","year":"2016","journal-title":"Lancet Oncol"},{"key":"43","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Wenger","year":"2017","journal-title":"N Engl J Med"},{"key":"44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00277-016-2878-5","article-title":"Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","volume":"96","author":"Sehn","year":"2017","journal-title":"Ann Hematol"},{"key":"45","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1158\/1078-0432.Ccr-14-0516","article-title":"Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia","volume":"20","author":"Shapiro","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T18:54:46Z","timestamp":1589050486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,6]]},"references-count":45,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2018,7,6]]}},"alternative-id":["25714","30042825"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25714","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,6]]}}}